Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia

Holly C Boyer, Patricia Fernandes, Chap T Le, Bevan Yueh

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: Our previous studies have demonstrated the tolerability and low side-effect profile of office-based sclerotherapy with sodium tetradecyl sulfate (STS) for treating recurrent epistaxis due to hereditary hemorrhagic telangiectasia (HHT). The objective of this study was to use a prospective randomized trial to determine the effectiveness of sclerotherapy with STS vs standard treatment. Methods: This prospective randomized trial (conducted from November 1, 2011, through January 31, 2014) involved 17 patients with recurrent epistaxis due to HHT. We defined standard treatment as continuation of any treatment that the patient had previously undergone, such as moisturization, packing, and cautery. We used a crossover design, so study participants were randomized to either sclerotherapy or standard treatment during the first time period, and then to the other during the second period. The primary outcome measure was frequency and severity of epistaxis, as measured by the epistaxis severity score (ESS). The ESS is a 10-point scale, with higher scores corresponding to more bleeding. Results: After controlling for treatment order, bleeding was substantially better controlled after sclerotherapy; the ESS after sclerotherapy was nearly one point lower than after standard treatment (-0.95, 1-sided p = 0.027). Treatment order, baseline ESS, the number of lesions, moisturization practices, and a history of previous blood transfusions did not significantly affect the results. Conclusion: This trial demonstrated that sclerotherapy with STS (vs standard treatment) significantly reduced epistaxis due to HHT.

Original languageEnglish (US)
Pages (from-to)435-440
Number of pages6
JournalInternational Forum of Allergy and Rhinology
Issue number5
StatePublished - May 1 2015

Bibliographical note

Publisher Copyright:
© 2015 ARS-AAOA, LLC.


  • Epistaxis
  • Hemorrhagic disorders
  • Osler-Weber-Rendu syndrome
  • Sclerotherapy
  • Sodium tetradecyl sulfate


Dive into the research topics of 'Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia'. Together they form a unique fingerprint.

Cite this